Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05675683 · ClinicalTrials.gov registry record
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
A clinical trial of Metastatic Non Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT05675683 is a study of Metastatic Non Small Cell Lung Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants, below the 391-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05675683, a study of Metastatic Non Small Cell Lung Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world practice settings. The study population consisted of patients with histologically confirmed stage IIIB, IIIC, or IV MET Exon 14 skipping mutated NSCLC with BM. The date of the initiation of therapy with capmatinib after the date of initial BM diagnosis at or after the initial advanced or metastatic NSCLC diagnosis defined the study index date. The 12-month period before the study index date defined the baseline period to assess baseline demographic and clinical characteristics. Study measures were assessed at the index and during the baseline and postindex date periods. The index date needed to occur between 1 May 2020 and the date of data abstraction, provided the selected patients meet the requirement of a minimum of 6 months follow-up time available after capmatinib initiation; the exceptions to this are those patients who died during this period.
Conditions Studied
Interventions
- DRUG Capmatinib
Study Locations (1)
New Jersey
- 18 Novartis Investigative Sites in the US - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05675683
The ClinicalTrials.gov registry entry for NCT05675683 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 391-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Capmatinib is the first listed.
NCT05675683 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05675683 about?
NCT05675683 is a clinical study titled "Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib". This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world practice settings. The study population consisted of patients with hi...
What is the current status of trial NCT05675683?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2021-10-01. Estimated completion is 2021-12-31.
What conditions does trial NCT05675683 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT05675683?
The interventions under investigation include: Capmatinib (DRUG).
Who is sponsoring clinical trial NCT05675683?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05675683 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RECRUITING · Phase 1
-
MOv19-BBz CAR T Cells in FRa+ Cancers
RECRUITING · Phase 1
-
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.